cellulitis_erysipelas
CELLULITIS/ERYSIPELAS
Cellulitis is a spreading bacterial skin infection that infects deeply involving the subcutaneous tissues.
It typically occurs in areas where the skin integrity has been compromised.
It may also result from blood-borne spread of infection to the skin and subcutaneous tissues.
It is commonly caused by beta-hemolytic streptococci and Staphylococcus aureus.
Erysipelas is a type of cellulitis with margins that are sharply demarcated, involves the epidermis and superficial lymphatics.
Onset of symptoms is acute whereas cellulitis has an indolent course.
It is more commonly caused by beta-hemolytic streptococci.

Cellulitis_erysipelas Management

Prevention

  • Predisposing factors should be identified and removed if possible 
  • Preventive measures may be helpful in reducing recurrent skin infections in patients with at least 2 separate episodes in the past 12 months
    • Consider previous microbiological test results and antibiotic history when choosing antibiotic agent 
    • Staphylococcal infection: Oral Clindamycin
    • Beta-hemolytic streptococcal infection: Penicillin or Erythromycin for 4-52 weeks or Benzathine penicillin intramuscular (IM) injections every 2-4 weeks
    • Treatment may be continued for several months with interval relapse assessment
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, Yesterday

Patients with coronavirus disease 2019 (COVID-19) who have haematologic malignancies have a 28 percent mortality rate, according to data collected from 250 patients by the ASH Research Collaborative COVID-19 presented at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020).

Roshini Claire Anthony, 01 Dec 2020

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.

Pearl Toh, 5 days ago
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.
Tristan Manalac, 2 days ago
People are more likely to follow social distancing measures for the novel coronavirus disease (COVID-19) pandemic when they thought that their friends and family did the same, too, according to a new study.